Related Experiment Videos
[Does the appearance of pro-arrhythmic response to anti-arrhythmic drugs have prognostic significance?]
M Trusz-Gluza1, L Giec, A Dabrowski
1I Kliniki Kardiologii IK Sl. AM Katowicach.
Insights
Proarrhythmic responses to antiarrhythmic drugs increase cardiac death risk in ischemic heart disease patients. Identifying and eliminating these proarrhythmic effects is crucial for improving survival in this vulnerable population.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Context:
- Ischemic heart disease (IHD) patients often have ventricular arrhythmias.
- Assessing the proarrhythmic potential of antiarrhythmic drugs is critical for patient safety.
- Previous studies have not fully elucidated the long-term cardiac mortality risk associated with drug-induced proarrhythmia in IHD.
Purpose:
- To determine if a proarrhythmic response to antiarrhythmic drugs is a significant risk factor for cardiac death in patients with IHD.
- To evaluate the incidence of proarrhythmia across different antiarrhythmic agents.
- To assess the long-term survival outcomes in IHD patients experiencing proarrhythmic events.
Summary:
- A study involving 782 IHD patients with ventricular ectopic beats (VEBs) conducted 1041 drug tests.
- Proarrhythmia, defined by increased VEBs or new ventricular tachycardia/fibrillation, occurred in 8.4% of patients and 7.9% of tests.
- Antiarrhythmic drugs inducing proarrhythmia were discontinued, and patients were followed for a mean of 22 months.
Impact:
- Patients experiencing proarrhythmia had a significantly higher risk of cardiac death at 1 and 3 years compared to those without proarrhythmic events.
- Findings highlight the importance of monitoring for and managing drug-induced proarrhythmia in IHD patients.
- This research contributes to optimizing antiarrhythmic drug selection and improving long-term survival strategies in IHD management.
Abstract:
Study was undertaken to assess whether proarrhythmic response to antiarrhythmic drug is a risk factor for cardiac death in patients (pts) with ischaemic heart disease (IHD). In 782 pts with IHD and frequent and/or complex ventricular ectopic beats (VEB) 1041 drug tests guided by 24 hour Holter monitoring were conducted. The following drugs were assessed: propranolol, disopyramide, mexiletine, amiodarone. Pro-arrhythmia was defined according to Velebit: 1/greater than or equal to 4-fold increase in VEBs, 2/greater than or equal to 10-fold increase in repetitive forms of 3/new occurrence of ventricular tachycardia or ventricular fibrillation (VT/VF). Proarrhythmic effect was observed in 8.4% of pts and in 7.9% of drug tests. The frequency with individual drugs ranged from 5.7% to 9%. No drug was completely free of this type of reaction. Antiarrhythmic drugs inducing arrhythmogenic response were eliminated. Pts were followed-up for a mean of 22 months (range 1-49). Chronic antiarrhythmic treatment was conducted. Pts were discharged taking the agent deemed most effective for suppression of arrhythmia. Follow-up visits were made every 6-12 months. All cases of death were verified. In long-term observation cardiac death and sudden death occurred in 53 and 32 pts. With actuarial analysis (Kaplan-Meler method, log rank test) there was significant difference in cardiac death (p less than 0.05) of pro-arrhythmia (+) compared with ++pro-arrhythmia (-) pts at yr (11% v 4%, 7% v 3%) and 3 yr (24% x 11%, 16% v 7%). The relative importance of baseline clinical variables in predicting survival was assessed with a stepwise Cox regression.(ABSTRACT TRUNCATED AT 250 WORDS)